ELTX
NASDAQ HealthcareElicio Therapeutics, Inc. - Common Stock
Biotechnology
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $11.49 |
|---|---|
| Volume | 118,882 |
| Market Cap | 219.30M |
| RSI (14-Day) | 56.8 |
| 200-Day MA | $9.96 |
| 50-Day MA | $10.86 |
| 52-Week High | $14.93 |
| 52-Week Low | $7.37 |
| Forward P/E | -6.53 |
| Price / Book | -149.22 |
๐ฏ Investment Strategy Scores
ELTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (58/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ELTX in your text
Paste any article, transcript, or post โ the tool will extract ELTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.